Concert Pharmaceuticals Inc (CNCE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Concert Pharmaceuticals Inc (CNCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9797
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Concert Pharmaceuticals Inc (Concert Pharmaceuticals) is a clinical stage biotechnology company which discovers and develops small molecule drugs. The company develops its products using its deuterated chemical entity (DCE) platform to develop novel therapeutics for autoimmune and inflammatory diseases, pulmonary diseases, and disorders of central nervous system (CNS). Its product pipeline includes CTP-543 (deuterated ruxolitinib) for alopecia areata; AVP-786 (deuterated dextromethorphan) indicated for alzheimer’s agitation, major depressive disorder and residual schizophrenia; CTP-730 (deuterated apremilast) for inflammatory diseases; CTP-692, a selective DCE modified analog of the endogenous amino acid, D-serine for Schizophrenia, and JZP-386 (deuterated sodium-oxybate) for narcolepsy. It employs its deuterated compounds to reduce the extent of metabolism in the wall of the intestines and in the liver. Concert Pharmaceuticals is headquartered in Lexington, Massachusetts, the US.

Concert Pharmaceuticals Inc (CNCE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Concert Pharma Raises USD30 Million in Venture Debt Financing 10
Partnerships 11
Concert Pharma Enters Into Co-Development Agreement With Celgene 11
Concert Pharma Enters Into Co-Development Agreement With Fast Forward For C-21191 12
Licensing Agreements 13
Processa Pharma Enters into Licensing Agreement with Concert Pharma 13
Processa Pharma Enters into Option Licensing Agreement with Concert Pharma 14
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 15
Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 17
Equity Offering 19
Concert Pharma Files Shelf Registration Statement with SEC to Raise USD250 Million 19
Concert Pharma Raises USD50 Million in Public Offering of Shares 20
Concert Pharma Completes Underwriters Exercise Of Over-Allotment Option Of IPO For US$93 Million 22
Asset Transactions 24
Vertex Pharma Acquires CTP-656 from Concert Pharma 24
Concert Pharmaceuticals Inc – Key Competitors 26
Concert Pharmaceuticals Inc – Key Employees 27
Concert Pharmaceuticals Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 01, 2018: Concert Pharmaceuticals reports third quarter 2018 financial results and provides company update 29
Aug 02, 2018: Concert Pharmaceuticals reports second quarter 2018 financial results and provides company update 30
May 03, 2018: Concert Pharmaceuticals Reports First Quarter 2018 Financial Results 31
Mar 01, 2018: Concert Pharmaceuticals Reports Year Ended 2017 Financial Results 33
Nov 09, 2017: Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update 34
Aug 08, 2017: Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Company Update 35
May 02, 2017: Concert Pharmaceuticals Reports First Quarter 2017 Financial Results 37
Mar 06, 2017: Concert Pharmaceuticals Reports Year Ended 2016 Financial Results 38
Corporate Communications 40
Dec 18, 2017: Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial Officer 40
Dec 13, 2017: Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index 41
May 30, 2017: Concert Pharmaceuticals Announces Departure of Chief Financial Officer, Ryan Daws 42
Product News 43
02/28/2018: Concert Pharmaceuticals Announces Advancement of Novel Drug Candidate in Schizophrenia 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Concert Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Concert Pharma Raises USD30 Million in Venture Debt Financing 10
Concert Pharma Enters Into Co-Development Agreement With Celgene 11
Concert Pharma Enters Into Co-Development Agreement With Fast Forward For C-21191 12
Processa Pharma Enters into Licensing Agreement with Concert Pharma 13
Processa Pharma Enters into Option Licensing Agreement with Concert Pharma 14
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 15
Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 17
Concert Pharma Files Shelf Registration Statement with SEC to Raise USD250 Million 19
Concert Pharma Raises USD50 Million in Public Offering of Shares 20
Concert Pharma Completes Underwriters Exercise Of Over-Allotment Option Of IPO For US$93 Million 22
Vertex Pharma Acquires CTP-656 from Concert Pharma 24
Concert Pharmaceuticals Inc, Key Competitors 26
Concert Pharmaceuticals Inc, Key Employees 27
Concert Pharmaceuticals Inc, Subsidiaries 28

List of Figures
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Concert Pharmaceuticals Inc (CNCE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • First Derivatives plc (FDP):企業の財務・戦略的SWOT分析
    First Derivatives plc (FDP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • PT PLN (Persero):企業の戦略的SWOT分析
    PT PLN (Persero) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • DJO Finance LLC:企業の戦略的SWOT分析
    DJO Finance LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Ricoh Co Ltd (7752):企業の財務・戦略的SWOT分析
    Ricoh Co Ltd (7752) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Suncor Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Suncor Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Suncor Energy Inc. (Suncor) is an integrated energy company that mainly focuses on the development of Athabasca oil sands. It carries out development and up gradation of oil sands; offshore and ons …
  • Vedanta Ltd:企業の戦略・SWOT・財務情報
    Vedanta Ltd - Strategy, SWOT and Corporate Finance Report Summary Vedanta Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Olympus Corp (7733):医療機器:M&Aディール及び事業提携情報
    Summary Olympus Corporation (Olympus) provides precision machinery and instruments. It develops, manufactures and markets equipment and devices for medical, healthcare, imaging, information, and other industrial markets. It offers medical systems such as endotherapy devices, medical endoscopes and t …
  • Topy Industries Ltd:企業の戦略・SWOT・財務分析
    Topy Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Topy Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • IMI plc:企業の戦略・SWOT・財務情報
    IMI plc - Strategy, SWOT and Corporate Finance Report Summary IMI plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Exterran Corp (EXTN):石油・ガス:M&Aディール及び事業提携情報
    Summary Exterran Corp (Exterran) is an energy service company that provides compression, production and processing products; and offers services that support the production and transportation of oil and natural gas. The company owns and operates natural gas compression equipment; and crude oil and n …
  • Ferndale Pharma Group Inc-製薬・医療分野:企業M&A・提携分析
    Summary Ferndale Pharma Group Inc (Ferndale Pharma), formerly Ferndale Laboratories Inc is a manufacturer and distributor of pharmaceutical products. The company provides surgical instruments, medical supplies, skin care products, topical therapeutic products, prescription, over the counter products …
  • Actuated Medical Inc:企業の製品パイプライン分析2018
    Summary Actuated Medical Inc (Actuated Medical) is a medical device company that develops minimally invasive instruments. The company provides products such as controlled tissue penetration systems, occlusion clearing systems and MRI compatible systems. Its controlled tissue penetration systems use …
  • McPherson’s Ltd (MCP):企業の財務・戦略的SWOT分析
    McPherson's Ltd (MCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • BL&H Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary BL&H Co Ltd (BL&H), a subsidiary of STADA Pharmaceuticals (Asia) Ltd is a drug company that manufactures and markets diagnostic test kits and drugs. The company offers products including aridol bronchial challenge test kit, cetraxal plus ear drop, al-sense amniotic leak test kit, DC bead-dru …
  • Alberta Health Services:企業の戦略的SWOT分析
    Alberta Health Services - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Xiwang Special Steel Company Limited:企業の戦略・SWOT・財務情報
    Xiwang Special Steel Company Limited - Strategy, SWOT and Corporate Finance Report Summary Xiwang Special Steel Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • ChemAxon Kft:医療機器:M&Aディール及び事業提携情報
    Summary ChemAxon Kft (ChemAxon) is a provider of software platforms. The company provides chemistry and biology software solutions and consultancy services that help in optimizing the value of chemistry information in life sciences and research and development. Its product portfolio consists of desk …
  • Altin Yunus Cesme Turistik Tesisler A.S.:企業の戦略・SWOT・財務分析
    Altin Yunus Cesme Turistik Tesisler A.S. - Strategy, SWOT and Corporate Finance Report Summary Altin Yunus Cesme Turistik Tesisler A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Houghton Mifflin Harcourt Company:企業のM&A・事業提携・投資動向
    Houghton Mifflin Harcourt Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Houghton Mifflin Harcourt Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Nuformix Plc (NFX):製薬・医療:M&Aディール及び事業提携情報
    Summary Nuformix Plc (Nuformix), formerly Levrett plc, is a pharmaceutical company which develops cocrystal forms of approved small molecules. Its product candidates which are in clinical and pre-clinical development include NXP001, NXP002, and NXP003 for the treatment of oncology supportive care an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆